Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 3

3(33.3%)

Phase 1

3(33.3%)

Phase 2

3(33.3%)

9Total

Phase 3(3)

Phase 1(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06514508Phase 3Recruiting

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

Role: lead

NCT05978401Phase 1Not Yet Recruiting

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Role: lead

NCT05909436Phase 1Recruiting

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Role: lead

NCT05900765Phase 2Recruiting

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Role: collaborator

NCT03713905Phase 1Completed

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Role: lead

NCT05798819Phase 3Not Yet Recruiting

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Role: lead

NCT05518318Phase 3Unknown

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Role: lead

NCT03655483Phase 2Unknown

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Role: lead

NCT03972722Phase 2Unknown

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Role: lead

All 9 trials loaded